The US Food and Drug Administration (FDA) first approved the use of SGLT2 inhibitors in 2013 for patients with T2DM, and the first study was published in 2016, which demonstrated their beneficial effects in terms of delaying diabetic kidney disease (DKD) progression [12]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.